GSK481
Catalog No. A12615
GSK481是新型的RIP1抑制剂苯并a庚酮(BOAz)系列。受体相互作用蛋白激酶1(RIP1)已被认为是通过调节程序性坏死调节炎症的关键因素。已显示对该激酶的抑制作用可阻止细胞坏死,从而将RIP1确定为潜在治疗多种炎性疾病的可行靶标。
Catalog Num | A12615 |
---|---|
M. Wt | 377.39 |
Formula | C21H19N3O4 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 1622849-58-4 |
Synonyms | GSK 481, GSK-481 |
SMILES | O=C(C1=NOC(CC2=CC=CC=C2)=C1)N[C@H]3COC4=CC=CC=C4N(C)C3=O |
GSK481是新型的RIP1抑制剂苯并a庚酮(BOAz)系列。受体相互作用蛋白激酶1(RIP1)已被认为是通过调节程序性坏死调节炎症的关键因素。已显示对该激酶的抑制作用可阻止细胞坏死,从而将RIP1确定为潜在治疗多种炎性疾病的可行靶标。
Targets
RIP1 | ||||
In vitro | DMSO | 70 mg/mL (185.48 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 26.5 mL | 132.49 mL | 264.98 mL |
0.5 mM | 5.3 mL | 26.5 mL | 53 mL |
1 mM | 2.65 mL | 13.25 mL | 26.5 mL |
5 mM | 0.53 mL | 2.65 mL | 5.3 mL |
*The above data is based on the productmolecular weight 377.39. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.